** Shares of drugmaker Eyenovia EYEN.O rise 6.1% to 11 cents premarket
** EYEN says it will take additional actions to reduce ongoing personnel-related costs by more than 70%
** Co adds investment firm Avenue Capital has agreed to restructure loan agreement and delay EYEN's debt repayments, including principal and interest, until February 2025
** As of Nov. 19, EYEN owed $10.1 million in principal and accrued interest under the agreement with Avenue Capital, according to a regulatory filing earlier this week
** EYEN had 57 full-time employees as of March 15, according to its latest annual report
** Co has been evaluating alternatives after its experimental drug-device combination for an eye disease failed in a late-stage study earlier this month
** As of last close, stock had fallen ~95% YTD
(Reporting by Kamal Choudhury in Bangalore)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.